SCHOTT Pharma
Balazs Vizi has a diverse work experience history. Balazs began their career at General Electric in 2001, where they held various roles such as OMLP and Plant Manager. Balazs then worked at Closure System International as the Managing Director of Hungary from 2010 to 2015. Following that, they joined Flextronics as the General Manager from 2015 to 2017. From 2018 to 2021, they served as the Managing Director and later as the Head of Regional Operations Europe Bulk Solutions at SCHOTT. Since 2021, they have continued in the same role at SCHOTT Pharma.
Balazs Vizi received a Master's degree in Electrical Engineering from Budapest University of Technology and Economics between 1994 and 2000.
This person is not in any offices
SCHOTT Pharma
1 followers
SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world – because human health matters. Every day, more than 4,700 people from 65 nations work at SCHOTT Pharma to contribute to global healthcare. The company has 17 manufacturing sites across major pharmaceutical hubs in Europe, the Americas and Asia. SCHOTT Pharma maintains a diverse portfolio of injectable drug containment and delivery solutions. These solutions range from prefillable glass and polymer syringes, cartridges, vials and ampoules. The company has focused on developing innovations for future technologies by: • Creating over 1000 patents and technologies developed in-house • Building a state-of-the-art Research and Development Center in Switzerland • Absorbing over 130 professionals focused on Research and Development Despite being a pharmaceutical manufacturer, SCHOTT Pharma aims to become climate-neutral by 2030. The company commits to this through sustainable development approaches in the society and the environment. Based in Mainz, Germany, it is part of SCHOTT AG that falls under the Carl Zeiss Foundation. SCHOTT Pharma has over 1700 global customers, 30 of which are the leading pharmaceutical manufacturers of injectable drugs. These customers have generated combined sales of EUR 899 million in the fiscal year 2023. Contact us now: pharma@schott.com Data protection: https://www.schott-pharma.com/en/legal-social